TrialArthritis research & therapy2016

Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study.

Elena Schiopu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.